Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Product Unit Size | Cost | Quantity | Stock |
|---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Cas No. | 1258595-14-0 |
|---|---|
| Purity | ≥99% |
| Formula | C29H32F2N3O7P |
| Formula Wt. | 603.56 |
| IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Synonym | LHC165 |
| Appearance | Pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Podophyllotoxin derivative; topoisomerase II in...
GHB agonist, D2/3 antagonist.
AMPK activator.
Endogenous tachykinin peptide, involved in infl...
Inhibitor of glutamic acid decarboxylase (GAD)....
ROCK1/2 inhibitor.
STAT3 inhibitor.
Active metabolite of losartan
Butyrophenone; σ2 agonist, α1-adrenergic, D2,...
Found in Paeonia; L-type Ca2+ channel blocker.<...
Xanthine oxidase inhibitor.
Islet β cell proliferation stimulator.
Polyether pyrrole, divalent cation ionophore.
Optically active cysteine derivative found in A...
Endogenous opioid peptide; μOr agonist.
Mineralocorticoid, aldosterone, AR antagonist, ...
Xanthine derivative; adenosine A2 antagonist, P...
Oxidized non-cylic hexose sugar.
c-Raf inhibitor, tyrosine kinase inhibitor.
Endogenous peptide, involved in vascular contra...